ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $549.23 ($542.98–$551.87, $5.22M total) across 10 trades on 2026-06-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO/Chair’s $5.22M open-market sale of 9,500 shares on 2026-06-11, executed under a pre-arranged 10b5-1 plan.
Market read
This provides fresh, primary-source information on insider selling, but the 10b5-1 structure limits interpretive power for price action.
What to watch
Traders should compare this sale size/cadence to prior Form 4 patterns; one-off planned sales often have little predictive value.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics.
Ticker impact
United Therapeutics CEO/Chair Martine Rothblatt sold $5.22M of UTHR shares via an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited/short-lived impact; watch for follow-through only if selling accelerates beyond planned cadence.
The filing is a primary-source Form 4 showing a direct officer sale, but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens interpretive value.
Market effects
Minimal; this is company-specific insider activity with no stated operational/regulatory change.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity planning rather than a bearish view on fundamentals.
Key entities
- issuerUNITED THERAPEUTICS Corp
Subject of the Form 4 insider transaction disclosure.
- insiderROTHBLATT MARTINE A
Chairperson & CEO who sold shares.
